Malaria drug development remains an important public health goal, especially in light of the emergence of drug resistance. Here a new class of malaria drugs is presented: an acridone derivative containing a chemosensitizing domain that may prevent the occurrence of parasite drug resistance.
- Jane X. Kelly
- Martin J. Smilkstein
- Michael K. Riscoe